The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | NSCLC: identifying patients most likely to relapse
Charles Swanton, FRCP, BSc, PhD from the Francis Crick Institute, London, UK speaks about his recent paper on the use of phylogenetic ctDNA analysis to predict relapse following surgery for non-small cell lung cancer (NSCLC). Investigation into a patient’s plasma after surgery and detection of point mutations allowed physicians to identify which patients are more likely to relapse. This was associated with the level of cfDNA that was detected in patient’s plasma. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.
